Results
EXPLORE ASCERTAIN’S RESEARCH FINDINGS, TOOLS, AND POLICY OUTPUT
This page provides access to the results of the ASCERTAIN project. In line with our commitment to transparency and open science, all project outcomes will be made publicly available here as they are developed.
Our results will include:
- Key findings from the project’s research activities
- Tools and resources developed within ASCERTAIN
- Policy recommendations and position papers
- Materials from stakeholder engagement activities
PUBLICACIONES
- Kaló, Z., Rutten-van Mölken, M., Aas, E., Salcher-Konrad, M., Tesař, T., Belleman, T., et al. (2026). Principles of selecting cost-effectiveness thresholds in price-taker countries. Expert Review of Pharmacoeconomics & Outcomes Research. Advance online publication. https://doi.org/10.1080/14737167.2026.2715977
- Wu, Y. S., Burger, E. A., Holmboe, F., Bangum, M., Oteiza, F., Bugge, C., Sæther, E. M., & Aas, E. (2026). Integrating structured expert elicitation with external evidence to inform earlier reimbursement decisions: A Norwegian case study of selpercatinib for non-small cell lung cancer. PharmacoEconomics – Open. Advance online publication. https://doi.org/10.1007/s41669-026-00656-9
- Geisler, B. P., Holmboe, F., Starinieri, I., & Aas, E. (2026). Applications of structural expert elicitations for economic evaluations: A systematic review update. Pharmacoeconomics. Advance online publication. https://doi.org/10.1007/s40273-026-01628-x
- Xander NSH, Rutten-van Mölken MPMH, Bertin L, Miljković N, Uyl-de Groot CA. Legal implications of joint clinical assessments under the EU HTA regulation. Health Economics, Policy and Law. Published online 2026:1-13. doi:10.1017/S1744133126100413
- Xander, N.S.H., Belleman, T., Salcher-Konrad, M. et al. Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review. Eur J Health Econ (2025). https://doi.org/10.1007/s10198-025-01834-y
- Henkel, P. S., Aas, E., Russnes, H. G., Dyvik, I., Fagereng, G. L., Helland, Å., Røgenes, H., Lien, T. G., & Pedersen, K. (2025). Microcosting Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway. The Journal of Molecular Diagnostics. Advance online publication, July 22, 2025. https://doi.org/10.1016/j.jmoldx.2025.06.006
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot, Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands, Value in Health, 2024,
https://doi.org/10.1016/j.jval.2024.06.003 - Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, et al. (2024) Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLOS ONE 19(2): e0293264. https://doi.org/10.1371/journal.pone.0293264
- Uyl-de Groot, C. A., Xander, N.S.H., Belleman, T., Burger, E. A., Doeswijk, R., Durand-Zaleski, I., Geisler, B. P., Groene, O., Hendrickx, A., Henkel, P. S., Heine, R., Huić, M., Melli, M., Morgan, K., Racovița, M., Quinonez, G., Rutten-van Mölken, M. P. M. H., Tesař, T., Thielen, F. W., Schneider, P., Wu, Y. S., Salcher-Konrad, M., & Aas, E. (2026). Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN project. Health Policy and Technology, 15(2), 101155.
- Salcher-Konrad, M., Schneider, P., Zimmermann, N., & Hendrickx, A. (2025). Scoping review of definitions for fair prices of new health technologies (pre-print). OSF. https://osf.io/udsg4
- Uyl-de Groot CA, Xander NS, Hendrickx A, Salcher-Konrad M. Auf dem Weg zu einer gerechten und nachhaltigen Preisgestaltung im Gesundheitswesen: Fokus auf das AIM-Fair-Price-Modell und das ASCERTAIN-Projekt [Toward Equitable and Sustainable Medicine Pricing: Focus on the AIM Fair Price Model. and the ASCERTAIN project]. In: Schröder H, Thürmann PA, Thiede M, Enners S, Busse R (Eds.): Arzneimittel-Kompass 2025. Die Preisfrage: Wege zu fairen Lösungen [Medicines compass 2025. The question about the price. Approaches for fair solutions]. Springer, Berlin, 2025, p. 153-64
VÍDEO
- Kick-off Meeting
- Animated explainer video
- Behind the Scenes: Making the ‘3 Things About’ Series
- 3 Things About Market Access
- 3 Things About Tiered Pricing
- 3 Things About Pricing of New Drugs
- 3 Things About Reimbursement
- 3 Things About Cost-Effectiveness
- 3 Things About Value of New Cancer Drugs
- What is reference pricing?
- What is a list price for a medicine?
- What is a fair price?
- How do the views or perspectives of patients influence decisions on medicine access?
- What is a framework?
- The Journey of a Medicine
ACCESS2MEDS FRAMEWORK
PÓSTER
- Geisler, B.P., Meltzer, S., Burger, E.A., Aas, E., Ree, A.H. Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). Annals of Oncology. 2024;35:S936–S937.
DOI: https://doi.org/10.1016/j.annonc.2024.08.159 - Geisler, B.P., Meltzer, S., Burger, E.A., Ree, A.H., Aas, E. Cost-effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy. Abstract forthcoming in a Value in Health Supplement
- Salcher-Konrad, M. Pharmacoeconomic perspective on medicines prices and efficiency in health systems. pharmakon 2025.
- Salcher-Konrad, M. What is a fair price? Reviewing “fair pricing” definitions from different perspectives. EHA 2024 Congress.
- Salcher-Konrad, M., Hendrickx, A., Schneider, P., Zimmermann, N. Defining fair prices for new health technologies. 5th PPRI Conference 2024: Ensuring access to affordable medicines through innovative policies, Vienna, 25–26 April 2024.
- Salcher-Konrad, M., Zimmermann, N., Schneider, P., Hendrickx, A. What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies. ISPOR Europe 2023, Copenhagen, 14 November 2023.
- Salcher-Konrad, M., et al. «Fair» or «optimal» pricing of medicines: how do definitions for fair pricing align with economic theory? EuHEA 2024.
- Xander, et al. Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products. ISPOR Europe 2025
- Xander, et al. Determining and Applying Fair Prices of Innovative Health Technologies: A Stakeholder View Analysis. lolaHESG 2025.
- Xander, et al. Price Determinants and Pricing Policies Concerning Potentially Innovative Health Technologies: A Scoping Review. ISPOR Europe 2024
WEBINARIOS
- How Can Precision Medicine, Genetic Testing, and Biomarkers Support Better Healthcare Decisions? – June 2026
- How are costs and medicine effectiveness part of decision-making in medicine access? – October 2025
- How do different countries make decisions on reimbursing new medicines? – April 2025
- Basics of medicines pricing in Europe – March 2024
- Greener pharmaceuticals: policies for an environmentally sustainable pharmaceutical system
comunicados de prensa
OTROS
- Project glossary
- Interview for Dagens Medisin (news paper and trade magazine for Norwegian healthcare personnel and other employees within the healthcare sector): Camilla Ø. Ondrckova: “Nye, norske data kan føre til ny behandling for avansert tykktarmskreft” (in Norwegian) https://www.dagensmedisin.no/esmo-esmo-2024-forskning/nye-norske-data-kan-fore-til-ny-behandling-for-avansert-tykktarmskreft/651327
- Interview for Health Talk (website and video channel): «Er immunterapi mot tarmkreft kostnadseffektivt? Biomarkører kan være nøkkelen» (in English): https://www.healthtalk.no/tarmkreft/er-immunterapi-mot-tarmkreft-kostnadseffektivt-biomarkorer-kan-vaere-nokkelen/189801 (teaser)
- DM Arena Post ESMO (post-conference recap, organized by Dagens Medisin) https://www.dagensmedisin.no/dmarena/dm-arena-post-esmo-opptak-tilgjengelig-na/646377
- Vumedi video, summary of the ESMO talk https://www.vumedi.com/video/esmo-2024-insights-the-value-of-immune-checkpoint-blockade-in-msspmmr-mcrc/
Contacto
Ponte en contacto con nosotros si tienes alguna pregunta o comentario. Nos pondremos en contacto contigo lo antes posible.
Para preguntas relacionadas con la investigación:
Carin Uyl-de Groot
Coordinadora del proyecto
Universidad Erasmus de Rotterdam
ln.rue.mphse@lyu
Teléfono: +31 10 4081583
Para preguntas generales sobre el proyecto:
Marcel Langone Marques
Director del proyecto
Universidad Erasmus de Rotterdam
ln.rue@seuqramenognal.lecram
Teléfono: +31 10 4081583
Para comunicaciones:
Lena Jessen
Gestora del proyecto
OptiMedis
ed.sidemitpo@nessej.l
Teléfono: +49 40 226211490